EGFR and non-small cell lung carcinoma: Two out of five patients with EGFR-mutant NSCLC were positive for EGFR T790M mutation, a marker of sensitivity to osimertinib, and received clinical benefits from osimertinib therapy, achieving a partial response (PR) and relatively long progression-free survival (PFS)3.